Lyell Immunopharma jumps after FDA permits human trials of cancer treatment
06/10/2022 21:53
** Shares of Lyell Immunopharma Inc LYEL.O , a developer of
cellular therapies for cancer treatment, up 4.1% at $8.42 in
extended trading
** Co says U.S. Food and Drug Administration cleared its
Investigational New Drug (IND) application for LYL845, paving
way for an early-stage trial of the drug
** LYL845 is a potential treatment of melanoma and other
tumors urn:newsml:reuters.com:*:nGNX7L55NF
** LYEL will now start clinical trial for the drug and
expects initial data in 2024, co adds
** YTD as of Thursday's close, LYEL is up 2.5%
(Reporting by Niket Nishant in Bengaluru)
((Niket.Nishant@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma